Sign in
Taking people in AustriaPhase 2

Tests a bladder drug given directly into the bladder for low grade bladder cancer

Tests gemcitabine, given into the bladder, in adults with early low grade bladder cancer.

Key facts

Who runs it
Medical University Of Vienna
Where
Vienna, AustriaSee the site
Registry title
COBRA - Chemoablation for Low Grade Bladder Cancer: A single arm, prospective, open-label, investigator-initiated Phase 2 study
Status
Recruiting
Phase
Phase 2
People taking part
47 people, planned
Started
27 Dec 2023
Planned end
1 Apr 2026
Type of study
Interventional
Record updated
30 October 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a low-grade, non-invasive bladder cancer (TaLG) that has come back or is newly found. It tests gemcitabine placed in the bladder.

Age
18 years or older
Sex
All sexes can join
Disease stage
TaLG bladder cancer confirmed by a biopsy. Largest tumour 15 mm or smaller. No more than 5 tumours. No spread to lymph nodes or other organs.
Earlier treatment
No treatment placed inside the bladder within the last 1 year.
Biomarker or test result
Urine cell test negative for high-grade disease within 8 weeks before screening.

Main reasons for not taking part

  • High-grade bladder cancer in the last 3 years
  • Muscle-invasive or spread bladder cancer
  • Past cancer of the upper urinary tract
  • Positive HIV test
  • Pregnant or breastfeeding

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Diagnosis of a recurrent tumor and a history of TaLG BCa or diagnosis of primary TaLG BCa histologically confirmed by cold cup biopsy at screening or within 8 weeks before screening
  • Female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment. Female patients of childbearing potential must use adequate contraception during study period
  • Willing and able to provide informed consent
  • On screening cystoscopy: Diameter of the largest lesion ≤15mm
  • Number of lesions ≤5
  • Cystoscopy with bladder diagram including number, site, size and appearance of the tumors with photo documentation
  • Patient who has recurrence of and not other than TaLG NMIBC (low or intermediate EAU risk)
  • NMIBC requiring treatment with transurethral resection of bladder tumors (TURBT)
  • Negative voiding cytology for high grade (HG) disease within 8 weeks before Screening
  • No lymph node metastasis or distant metastasi
  • Male and female patients must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment

Who cannot take part

  • Evidence of active urinary tract infection (UTI) that in the Investigator's opinion cannot be treated and resolved prior to biopsy and/or administration of study treatment
  • Any previous intravesical therapy within 1 year
  • Previous HG NMIBC (within the last 3 years). It is allowed to include patients who had history of HG disease longer than 3 years ago
  • History of neurogenic bladder; active urinary retention; any other condition that would prohibit normal voiding
  • Positive human immunodeficiency virus (HIV) test
  • Past or current muscle invasive bladder cancer (i.e., T2, T3, T4) or metastatic UC
  • History of upper tract urothelial carcinoma (UTUC)
  • Tumors that clinicians suspect to be HG
  • Patient refused to participate
  • Female patients who are pregnant/breastfeeding
  • Female patients of childbearing potential not using adequate contraception
  • Positive HG cytology according to Paris criteria
  • Diameter of tumor >15 mm
  • Number of lesions >5
  • Clinically significant urethral stricture that would preclude passage of a urethral catheter

Where in Austria

  • Medical University of ViennaVienna, AustriaTaking people

About the trial

What the trial wants to find out

To assess efficacy of intravesical gemcitabine in patients with TaLG bladder cancer

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
COBRA - Chemoablation for Low Grade Bladder Cancer: A single arm, prospective, open-label, investigator-initiated Phase 2 study
Plain-language title
Tests a bladder drug given directly into the bladder for low grade bladder cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
30 October 2024